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Factors inﬂ uencing treatment decisions in this 
heavily-treated patient population in the UK
Decision-making strategies for optimal treatment of recurrent 
ovarian cancer (ROC) are complex as new cytotoxic drugs and 
an increasing number of biological agents become available. 
This presents challenges in deﬁ ning the optimal timing and 
sequencing of the drugs or treatment regimen. A controversial 
issue of ROC treatment concerns the lack of an OS advantage 
observed with a number of investigational compounds and 
regimens, and they can be often associated with increased 
toxicity and no improvements in patients’ QoL. Therefore, 
current treatment options for patients with ROC are frequently 
guided by safety considerations and convenience. A sub-
analysis of the OVA-301 study showed that for platinum-
sensitive patients (PFI >6 months), median progression-free 
survival was 9.2 months with the trabectedin + PLD combination 
vs 7.5 months with PLD monotherapy (hazard ratio, 0.73; 95% 
CI, 0.56 to 0.95; p=0.0170). In fact, the median overall survival in 
the patient subgroup with a platinum-free interval in excess 
of 12 months (considered to have very PS disease) was 36.5 
months with the combination, which was in the range of that 
obtained with platinum combinations [1].
Limitations to rechallenging with platinum-based 
therapy
Although therapeutic regimens that combine platinum-based 
therapy with other cytotoxic agents are the current standard 
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a b s t r a c t
Most patients with recurrent ovarian cancer (ROC) undergo a series of remissions and 
recurrences, therefore the additive or cumulative toxicity of chemotherapy must be factored 
into their treatment plan. There are challenges in deﬁ ning tailored therapeutic approaches, 
including optimal timing and drug sequencing management strategies to treat patients 
with ROC. This is particularly relevant as new cytotoxic drugs and biological agents become 
available. Many of these drugs are associated with increased toxicity and with no observable 
survival advantage. Therefore current treatment options for the heavily-pretreated relapsing 
OC patient population are frequently guided by safety considerations and convenience. 
Rechallenge with platinum-based combination regimes is commonly limited by the risk 
of cumulative long-term toxicities. Not all patients can continue with platinum at second-
line or, indeed, further relapses due to loss of activity or toxicity-related issues including 
hypersensitivity, neurotoxicity, alopecia and ototoxicity. In particular, hypersensitivity 
reactions are a concern and have been reported in approximately 15-20% of women receiving 
the drug. Trabectedin + PLD is a non-platinum combination that is well tolerated, with a 
manageable safety proﬁ le, which is independent of age.
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of care for advanced ovarian cancer patients, the cumulative 
toxicities of cisplatin and carboplatin can present barriers for 
the long-term use of these agents [2,3]. As previously discussed, 
there are women with relapsing disease (particularly the PPS 
subgroup) who would beneﬁ t from a delay in platinum re-
treatment to possibly enhance their response to platinum in a 
future application, or who are not ideal candidates for platinum-
based therapy due to the toxicity proﬁ le of platinum or due 
to platinum-induced toxicity. There appear to be three main 
limitations to using carboplatin combinations, including allergy 
to carboplatin (hypersensitivity), renal toxicity, and ototoxicity.
Hypersensitivity reactions (HSRs) to carboplatin are a 
particular concern, and have been reported in approximately 
15-20% of women [2]. Symptoms of carboplatin HSRs are highly 
variable and can be mistakenly attributed to other agents, 
particularly when they are used in combination. They include 
itching, rash, chest tightness, emesis, blood pressure changes 
and facial swelling. The onset of the carboplatin-associated 
HSR is also highly variable, occurring either as soon as the 
infusion starts or after it is completed. When expectations 
for a positive outcome with platinum are good, then 
desensitisation protocols may be useful to continue platinum-
based therapy, and success rates in excess of 50% have been 
reported [2]. However, for example a 12-step desensitization 
protocol that administers the total dosage of carboplatin at 
increasing doses and faster rates over an extended period of 
time, requires adequate support in an intensive care unit or 
allergy department. All with the attendant burden on stafﬁ ng 
and resources, and of course patient preference [1,2].
Other clinically signiﬁ cant sequelae such as neurotoxicity, 
severe cumulative myelosuppression, renal toxicity and oto-
toxicity are commonly caused by platinum-based chemo-
therapy. Indeed neurotoxicity, which inﬂ uences patient’s 
quality of life, is a dose-limiting adverse effect for all 
platinum compounds, and there is a high probability of per-
sis tent neurotoxicity including residual neuropathy (~20% 
of OC patients) associated with carboplatin plus paclitaxel 
treatment [4]. Carboplatin causes dose-limiting and 
cumulative myelosuppression, characterised by frequent and 
severe thrombocytopenia, granulocytopenia and anaemia. 
Likewise, cisplatin is associated with several cumulative and 
irreversible toxicities, including dose-dependent renal tubule 
toxicity and neurotoxicity [5]. Cumulative doxorubicin and 
paclitaxel exposure must also be monitored to minimize the 
risk of patient morbidity due to cardiotoxicity and neuropathy. 
Gemcitabine has many overlapping toxicities with other 
agents, and care must be taken with combination regimens to 
avoid synergy of these adverse effects [3].
Toxicity issues should be carefully taken into account 
before considering platinum re-treatment, as the platinum-
associated cumulative and irreversible toxicities may 
jeopardise its long-term intervention on subsequent relapses. 
Consideration of platinum-induced cumulative toxicity takes 
on greater signiﬁ cance as the number of salvage regimens 
increase, as it can be given only to those patients for whom 
the toxicities would be acceptable. This underscores the need 
for alternative therapeutic options, including an efﬁ cacious 
non-platinum regimen with an acceptable toxicity proﬁ le.
Other factors that inﬂ uence treatment decisions in this 
heavily-treated patient population have to be taken into 
account. For example, efﬁ cacy (clinical or symptom beneﬁ t), 
safety (speciﬁ cally limitations with carboplatin due to 
hyper sensitivity or residual toxicities) and QoL need to be 
considered. This could include health-related QoL, patient-
reported outcomes regarding symptoms, and time without 
symptoms or toxicity. For example, although temporary in 
nature, alopecia is a visible reminder of cancer treatment 
and is extremely upsetting for many women. A recent pan-
European survey into the QoL of 1743 patients with ovarian 
cancer by Oskay-Ozcelik et al. reported that alopecia was 
the single most troublesome side effect, with 42% patients 
reporting being bothered by alopecia [6]. It is known that 
platinum monotherapy and in combination with taxane does 
cause alopecia.
Furthermore, there is now an increasing body of evidence 
which shows that extending the platinum-free interval in 
relapsing patients with partially platinum sensitive ovarian 
cancer, also improves their response rate to platinum re-
treatment at a later time point [7].
Trabectedin plus PLD is a non-platinum 
combination that is well tolerated with a 
manageable safety proﬁ le
Clinical evidence from OVA-301 shows that the toxicity 
related to the trabectedin + PLD combination was acceptable. 
The most common adverse events with the trabectedin + 
PLD combination were neutropenia and transient increased 
transaminase levels (Box 1 and Table 1). The results show that 
neutropenia followed a predictable pattern of rapid onset and 
reversibility and, similarly, transaminase increases appear 
early after administration (during treatment cycles one and 
two), then generally decrease in incidence and severity with 
subsequent treatment cycles (Fig. 1). Hence the clinician can 
assess the impact of the combination therapy on the patient 
from the ﬁ rst 2 cycles.
The impact of trabectedin plus PLD combination 
on patients’ QoL
The impact of the trabectedin + PLD combination was also 
assessed on patients’ QoL via QLQ-C30, a standardised QoL 
instrument developed by the EORTC to assess the quality 
Box 1 – Main treatment-related adverse events reported 
in OVA-301 [1,8]
• Neutropenia - followed a predictable pattern of rapid onset 
and reversibility
• Most transaminase elevations improved to grade 1 or to pre-
treatment levels within 15 days, and less than 2% of cycles 
had recovery times >25 days. ALT and AST increases did not 
follow a cumulative pattern but showed a tendency towards 
less severe elevations over time
• Trabectedin + PLD is less frequently associated with the 
toxicity proﬁ le shown with PLD monotherapy:
 – Hand-foot syndrome
 – Mucositis/stomatitis
• No detriment in QoL was observed adding trabectedin + PLD 
vs. PLD alone (all randomised patients)
 – Trabectedin + PLD had no decrement in patient-reported 
functional status and symptoms compared with PLD alone
 – Trabectedin + PLD is less frequently associated with 
alopecia, which can impact patients’ QoL
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of life of cancer patients. Results from OVA-301 showed no 
difference in patients’ QoL between the 2 study arms (Fig. 2) 
[10].
Conclusions
During the course of their illness, patients with ovarian cancer 
may undergo multiple cycles of treatment, with alternating 
multiple episodes of remission and relapse. Therefore ROC 
patients are treated over a continuum in which therapeutic 
choices and strategies may impact the efﬁ cacy and safety 
of future therapies. Platinum rechallenge in combination or 
monotherapy regimes are often limited by hypersensitivity 
reactions and cumulative long-term toxicities, regardless 
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Dose Reduction: 18 (5%)
Dose Delay: 12 (4%)
Non-cumulative
Reversible
Fig. 1 – Mean transaminase levels (ALT) from all patients treated with trabectedin/PLD in OVA-301. The majority of elevations 
in transaminase levels were non-cumulative and reversible in OVA-301 [9]. Reprinted with permission. © 2014 American 





















Baseline C3 C5 C7 C9 C11
 PLD 303 209 159 71 42 22
N
 T+PLD 312 236 182 109 61 41
PLD
Trabectedin+PLD
Fig. 2 – OVA-301: QLQ-C30 global health status scale, mean score over time in all randomised patients. There was no 
difference in QoL, assessed by QLQ-C30, between the 2 study arms in the overall study population [10]. Reprinted with 
permission. © 2014 American Society of Clinical Oncology. All rights reserved.
Table 1 – Selected grade 3-4 clinically relevant 
symptomatic AEs from OVA-301 [9]
 PLD  Yondelis + PLD
 n=330 (%) n=333 (%)
Hand-foot syndrome 20 4
Mucosal inﬂ ammation 6 2
Stomatitis 5 1
Trabectedin + PLD is well tolerated with a manageable 
safety proﬁ le, the most common serious adverse events are 
neutropenia and transient increased transaminases, which 
appear early and generally decrease in incidence and intensity 
over subsequent cycles. 
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of the regimen. Desensitisation protocols may be useful so 
as to allow treatment to continue, albeit with signiﬁ cant 
burden on stafﬁ ng and resources and with varying outcomes. 
The safety data from OVA-301 show that trabectedin + PLD 
can be considered as a treatment option at any relapse of 
ovarian cancer, including fully platinum-sensitive patients 
unsuited to receive subsequent platinum, with a manageable 
safety proﬁ le and equivalent efﬁ cacy. Therefore, trabectedin 
+ PLD is a non-platinum alternative that is well tolerated. 
Furthermore, increasing evidence indicates that by extending 
the platinum-free interval with effective non-platinum agents 
such as trabectedin + PLD, patients are given some extra 
time to recover from any of the adverse effects of their prior 
platinum-based therapy with no detriment in QoL; and with 
even potential induction of their response to any subsequent 
platinum application, hence preserving their future treatment 
options.
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